The company also offers high-definition videoconferencing equipment in lieu of travel. Sanofi's 2023 revenue increased 0.2 percent year over year to nearly €43.1 billion. The company had about 86,100 ...

One of the cornerstones of being prepared for the next pandemic is being in the best position possible to design and deploy a ...

The U.S. FDA’s approval of yet another indication for Dupixent (dupilumab), partnered between Regeneron Pharmaceuticals Inc. and Sanofi SA, could mean another $6.4 billion-plus in sales by the end of ...

When debt is scarce and costly, it is hard for private equity investors to make deals stack up. That has been one reason for ...

Dupixent may help some people with inadequately controlled COPD who have a type of lung inflammation that worsens symptoms.

In a phase 3 trial, tolebrutinib has a significant effect on slowing disability progression in some patients with multiple sclerosis..

After psychological side effects doomed the first generation of cannabinoid receptor 1–targeting drugs for weight loss, Novo ...

Bill Berry, general manager life sciences and healthcare at Constellation and former head of US general medicines business ...

Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing ...

On September 20, the FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone in the first line for patients ...

I mean, I'd rather none ... Thanks also for the interest in Sanofi. We'll now close the call here in Copenhagen and wish everyone a great weekend. Thank you.